Back to top

Takeda completes seven-year Phase 3 TIDES trial of Qdenga

Takeda (TAK) announced the completion of the seven-year Phase 3 TIDES trial evaluating its dengue vaccine, Qdenga. These data, including an explora...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Takeda Pharmaceutical Co. (TAK)